RECALL RECORD — CLASS IIIRecall closedD-020-2014/FDA enforcement

Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2% and 2.5%, NET WT

What you need to know

Class III
  • What happened

    Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples.

  • Health risk

    The product is unlikely to cause adverse health consequences. These recalls are often related to labeling or quality violations. An allergen that is present but missing or incorrect on the label can cause a serious reaction in allergic consumers.

  • Action required

    Stop applying or using the product. Check the UPC and lot codes below, then return it to the retailer or contact the manufacturer about a refund or replacement.

Recall closed · classified by the FDADistribution not listedMore cosmetics

Advertisement

Ad

Know someone who bought this?

A quick share can keep a pantry check from becoming a missed warning.

Match before you discard

Product identification

Source: FDA COSMETICS

Brand nameValeant Pharmaceuticals North Am
Recalling firmValeant Pharmaceuticals North AmBridgewater, NJ, United States
UPC / barcodesNo UPC listed in the FDA enforcement record.
Lot / date codes
  • Lot AC27198F6
Distribution area

United States

United States

Quantity affected45, 000 tubes
Recall initiationFDA report date: December 4, 2013
FDA recall numberD-020-2014

Beyond the headline

The recall, in context

Valeant Pharmaceuticals North Am initiated this cosmetics recall on September 20, 2013. The FDA enforcement report states: Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples. The FDA report lists distribution as: United States.

The FDA enforcement report describes the reason as: Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples.

Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2% and 2.5%, NET WT was made or distributed by Valeant Pharmaceuticals North Am in Bridgewater, NJ, United States. This page reflects FDA report D-020-2014, dated December 4, 2013.

Why this is a Class III recall

Class III means the product is unlikely to cause adverse health consequences. These recalls are often related to labeling or quality violations. In this recall, an allergen that is present but missing or incorrect on the label can cause a serious reaction in allergic consumers.

FDA definition

The product is unlikely to cause adverse health consequences. These recalls are often related to labeling or quality violations.

What to do now

  1. 1

    Stop using it

    Set the product aside and do not apply it.

  2. 2

    Check the codes

    Compare the lot and date codes against the table above.

  3. 3

    Return or discard

    Contact the retailer or recalling firm about a refund, and dispose of the product safely.

Consumer safety guide

Undeclared allergen

Symptoms to watch for

Hives, swelling, wheezing, coughing, vomiting, abdominal pain or a drop in blood pressure. Anaphylaxis is a medical emergency.

When symptoms may appear

Allergic reactions often begin within minutes to a few hours of eating the allergen.

Higher-risk groups

Anyone with a diagnosed food allergy, especially children, and people with a history of anaphylaxis or asthma.

What to do now

  1. 1Do not eat or serve the affected product if you or anyone in the household has a diagnosed allergy.
  2. 2If symptoms such as swelling, wheezing or breathing difficulty occur, use the person's prescribed emergency plan and call emergency services.
  3. 3Keep the packaging, contact the retailer or manufacturer for a refund, and read the official recall notice for the exact allergen.

For a severe allergic reaction, do not wait for a callback or refund process before seeking emergency care.

This is general consumer safety information, not medical advice or a diagnosis. Follow the official recall notice and contact a healthcare professional if you have concerns about exposure or symptoms.

Frequently asked

Questions about this recall

What is the Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2% and 2.5%, NET WT recall?

Valeant Pharmaceuticals North Am recalled Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2% and 2.5%, NET WT in an FDA Class III enforcement action reported as D-020-2014. Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples.

What should I do if I bought this product?

Stop applying or using the product. Check the UPC and lot codes below, then return it to the retailer or contact the manufacturer about a refund or replacement. Do not eat or serve the affected product if you or anyone in the household has a diagnosed allergy. If symptoms such as swelling, wheezing or breathing difficulty occur, use the person's prescribed emergency plan and call emergency services. Keep the packaging, contact the retailer or manufacturer for a refund, and read the official recall notice for the exact allergen.

Is the Valeant Pharmaceuticals North Am recall still active?

The FDA lists this recall as recall closed. It remains relevant if you still have the affected product or need to identify a historical recall.

Where can I verify this recall?

This page is normalized from the openFDA enforcement record D-020-2014. You can verify it directly using the official source link on this page. VerifyRecall updates its index from public FDA enforcement data and does not replace advice from the FDA, the recalling firm or a healthcare professional.

Verify before you act.

VerifyRecall is independent and not affiliated with the FDA. Always confirm the latest status on the official source record.

Official source

Related alerts

Recent Undeclared allergens recalls

All alerts

Record last synced from official openFDA enforcement data on November 14, 2026. Source record: official FDA notice.